Pieris Pharmaceuticals (NASDAQ:PIRS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note released on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Stock Performance Shares of NASDAQ PIRS opened at $0.20 on Thursday. The firm has a market capitalization of $19.42 million, a price-to-earnings ratio […]

Leave a Reply

Your email address will not be published.

Previous post The Goldman Sachs Group Lowers Payoneer Global (NASDAQ:PAYO) Price Target to $7.00
Next post PayPal’s (PYPL) “In-Line” Rating Reiterated at Evercore ISI